

细胞色素P450酶的时间依赖性抑制研究及其在新药研发中的作用

立即下载

## Research advances of time-dependent inhibition of cytochrome P450 enzymes in drug discovery and development

谢珊珊;王盼;郭建军;詹彧;卜海之;陈西敬;

摘要:

细胞色素P450酶介导绝大多数药物的体内代谢,有些临床药物相互作用问题是由于药物对细胞色素P450酶的时间依赖性抑制引起的,但在传统的体外抑制筛选方法中并未包括对时间依赖性抑制的评价方案。本文综述了药物时间依赖性抑制的研究意义及评价方法(包括单点抑制法、IC<sub>50</sub>shift筛选法、酶动力学实验法等),并介绍如何利用所得体外数据进行临床预测。

关键词: 细胞色素P450;;时间依赖性抑制;;生物转化;;构效关系;;机理性抑制;;药物相互作用;;临床预测

基金项目: 苏州科学技术局姑苏创新创业领军人才基金资助(XG0826)

通讯作者: 谢珊珊;

**Email:**

参考文献:

- [1]WIENKERS LC,HEATH TG.Predicting in vivo drug interactions from in vitro drug discovery data [J].Nat Rev Drug Discov,2005,4(10):825-833.
- [2]MUKADAM S,TAY S,TRAN D,et al.Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput,automated assay:introducing a novel area under the curve shift approach[J].Drug Metab Lett,2012,6(1):43-53.
- [3]ZHOU S,CHAN E,LIM LY,et al.Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4[J].Curr Drug Metab,2004,5(5):415-442.
- [4]ZHOU S,YUAN CHAN S,CHER GOH B,et al.Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs[J].Clin Pharmacolinet,2005,44(3):279-304.
- [5]VANDENBRINK BM,ISOHERRANEN N.The role of metabolites in predicting drug-drug interactions:focus on irreversible cytochrome P450 inhibition[J].Curr Opin Drug Discov Devel,2010,13(1):66-77.
- [6]KALGUTKAR AS,OBACH RS,MAURER TS.Mechanism-based inactivation of cytochrome P450 enzymes:chemical mechanisms,structure-activity relationships and relationship to clinical drug-drug

扩展功能

● 本文信息

[PDF\(1699K\)](#)

[参考文献](#)

● 服务与反馈

[引用本文](#)

● 本文关键词相关文章

[细胞色素](#)

[P450](#)

[时间依赖性抑](#)

[制](#)

[生物转化](#)

[构效关系](#)

[机理性抑制](#)

[药物相互作用](#)

[临床预测](#)

● 本文作者相关文章

[谢珊珊](#)

[王盼](#)

- interactions and idiosyncratic adverse reactions[J].Curr Drug Metab,2007,8(5):407-447.
- [7]ORR ST,RIPP SL,BALLARD TE,et al.Mechanism-basedinactivation(MBI)of cytochrome P450 enzymes:structureactivity relationships and discovery strategies to mitigate drugdrug interaction risks [J].J Med Chem,2012,55(11):4896-4933.
- [8]LI AP.A review of the common properties of drugs withidiosyncratic hepatotoxicity and the “multiple determinanthypothesis” for the manifestation of idiosyncratic drug toxicity[J].Chem Biol Interact,2002,142(1-2):7-23.
- [9]BAROZZI N,TETT SE.What happened to the prescribing of other COX-2 inhibitors,paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia[J].Pharmacoepidemiol Drug Saf,2007,16(11):1184-1191.
- [10]KARIALAINEN MJ,NEUVONEN PJ,BACKMAN JT.Rofecoxibis a potent,metabolism-dependent inhibitor of CYP1A2:implications for in vitro prediction of drug interactions[J].DrugMetab Dispos,2006,34(12):2091-2096.
- [11]WANDEL C,KIM RB,GUENGERICH FP,et al.Mibefradil isa P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro[J].Drug Metab Dispos,2000,28(8):895-898.
- [12]DIXON DL,WILLIAMS VG.Interaction between gemfibrozil andwarfarin:case report and review of the literature[J].Pharmaco-therapy,2009,29(6):744-748.
- [13]AHMAD S.Gemfibrozil:interaction with glyburide[J].South MedJ,1991,84(1):102.
- [14]WEN X,WANG JS,BACKMAN JT,et al.Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9[J].Drug MetabDispos,2001,29(11):1359-1361.
- [15]YIN OQ,TOMLINSON B,CHOW MS.CYP2C9,but notCYP2C19,polymorphisms affect the pharmacokinetics andpharmacodynamics of glyburide in Chinese subjects[J].ClinPharmacol Ther,2005,78(4):370-377.
- [16]OQILVIE BW,ZHANG D,LI W,et al.Glucuronidationconverts gemfibrozil to a potent,metabolism-dependent inhibitorof CYP2C8:implications for drug-drug interactions[J].DrugMetab Dispos,2006,34(1):191-197.
- [17]US Food and Drug Administration.Guidance for Industry.Druginteraction studies-study design,data analysis,and implicationsfor dosing and labeling recommendations[EB/OL].(2012-02-01)[2012-10-29].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
- [18]GRIMM SW,EINOLF HJ,HAIL SD,et al.The conduct of invitro studies to address time-dependent inhibition of drug-metabolizing enzymes:a perspective of the pharmaceuticalresearch and manufacturers of America[J].Drug Metab Dispos,2009,37(7):1355-1370.
- [19]OLKKOLA KT,ARANKO K,LUURILA H,et al.A potentiallyhazardous interaction between erythromycin and midazolam[J].Clin Pharmacol Ther,1993,53(3):298-305.
- [20]GASCON MP,DAYER P.In vitro forecasting of drugs which mayinterfere with the biotransformation of midazolam[J].Eur J ClinPharmacol,1991,41(6):573-578.
- [21]LARREY D,FUNCK-BRENTANO C,BREIL P,et al.Effectsof erythromycin on hepatic drug-metabolizing enzymes in humans[J].Biochem Pharmacol,1983,32(6):1063-1068.
- [22]ZIMMERLIN A,TRUNZER M,FALLER B.CYP3A time-dependent inhibition risk assessment validated with 400reference drugs[J].Drug Metab Dispos,2011,39(6):1039-1046.
- [23]LI AP,DOSHI U.Higher throughput human hepatocyte assaysfor the evaluation of time-dependent inhibition of CYP3A4[J].Drug Metab Lett,2011,5(3):183-191.
- [24]WATANABE A,NAKAMURA K,OKUDAIRA N,et al.Riskassessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assaysystems and its application in the early drug discovery process[J].Drug Metab Dispos,2007,35(7):1232-1238.

[郭建军](#)

[詹彥](#)

[卜海之](#)

[陈西敬](#)

● 中国知网

[谢珊珊](#)

[王盼](#)

[郭建军](#)

[詹彥](#)

[卜海之](#)

[陈西敬](#)

Copyright by 中国新药与

- [25] OBACH RS, WALSKY RL, VENKATAKRISHNAN K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions[J]. *Drug Metab Dispos*, 2007, 35(2):246-255.
- [26] KAJBAF M, LONGHI R, FONTANA S. Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI)[J]. *Drug Metab Lett*, 2011, 5(2):104-113.
- [27] PERLOFF ES, MASON AK, DEHAL SS, et al. Validation of cytochrome P450 time-dependent inhibition assays: a two-timepoint IC50 shift approach facilitates kinetic assay design [J]. *Xenobiotica*, 2009, 39(2):99-112.
- [28] PARKINSON A, KAZMI F, BUCKLEY DB, et al. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes[J]. *Drug Metab Dispos*, 2011, 39(8):1370-1387.
- [29] BERRY LM, ZHAO Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes[J]. *Drug Metab Lett*, 2008, 2(1):51-59.
- [30] GHANBARI F, ROWLAND-YEO K, BLOOMER JC, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation[J]. *Curr Drug Metab*, 2006, 7(3):315-334.
- [31] ALBAUGH DR, FULLENWIDER CL, FISHER MB, et al. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems[J]. *Drug Metab Dispos*, 2012, 40(7):1336-1344.
- [32] KANAMITSU SI, ITO K, GREEN CE, et al. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4 [J]. *Pharm Res*, 2000, 17(4):419-426.
- [33] CHEN Y, LIU L, MONSHOUWER M, et al. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions[J]. *Drug Metab Dispos*, 2011, 39(11):2085-2092.
- [34] XU L, CHEN Y, PAN Y, et al. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator[J]. *Drug Metab Dispos*, 2009, 37(12):2330-2339.
- [35] BAER BR, DELISLE RK, ALLEN A. Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition[J]. *Chem Res Toxicol*, 2009, 22(7):1298-1309.
- [36] LU P, SCHRAG ML, SLAUGHTER DE, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor[J]. *Drug Metab Dispos*, 2003, 31(11):1352-1360.
- [37] WANG YH, JONES DR, HALL SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites[J]. *Drug Metab Dispos*, 2004, 32(2):259-266.
- [38] 郭建军, 赵华, 王晶晶. CYP介导的抑制性药物相互作用的体外定量预测[J]. *中国临床药理学与治疗学*, 2009, 14(8):841-848.
- [39] OBACH RS, WALSKY RL, VENKATAKRISHNAN K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions[J]. *J Pharmacol Exp Ther*, 2006, 316(1):336-348.
- [40] WANG YH. Confidence assessment of the simcyp time-based approach and a static mathematic model in predicting clinical drug-drug interactions for mechanism-based CYP3A[J]. *Drug Metab Dispos*, 2010, 38(7):1094-1104.
- [41] KANAMITSU S, ITO K, SUGIYAMA Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver[J]. *Pharm Res*, 2000, 17(3):336-343.

[42]ROSTAMI-HODJEGAN A,TUCKER GT. “In silico” simulationsto assess the “in vivo” consequences of “in vitro” metabolicdrug-drug interactions[J].Drug Discov Today Tech,2004,1:441-448.

[43]JAMEI M,MARCINIAK S,FENG K,et al.The Simcyppopulation-based ADME simulator [J].Expert Opin Drug MetabToxicol,2009,5(2):211-223.